YOU ARE HERE >> Project / GW Pharmaceuticals / Personnel
 Personnel / Advisors
 Executive Chairman
 Scientific Director
 Managing Director
 Finance Director
 Medical Director
 Director of Research & Development Operations
 Associate Technical Director
 Medical Director(North America)
 Special Counsel
 Head of Research Resources
 Clinical Research Manager
 Formulation Manager
 Regulatory Affairs Manager
For those who wish to help the Project, a registered charity has been set up to fund research in this area and on-line donations can be made.
Can't find what you want?

Executive Chairman
 Dr Geoffrey W Guy, MB BS, MRCS Eng, LRCP, LMSSA, BSc, Dip Pharm Med
Dr Guy is a physician with eighteen years experience in pharmaceutical development covering new chemical entities, biotechnology products, plant-based medicines and drug delivery systems. Dr Guy has been the physician in charge of over 350 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics, dose ranging, controlled clinical trials and large scale multi-centred studies and clinical surveys.

In 1985 Dr Guy founded the drug delivery company Ethical Holdings plc, of which he was Chairman and Chief Executive. In 1990, Dr Guy founded the plant medicines company Phytpharm plc, of which he was Chairman until 1997. Dr Guy served as director of clinical developments at Napp Laboratories from 1983 to 1985 and as international clinical research co-ordinator at Laboratories Pierre Fabre from 1981 to 1983.

Dr Guy gained a BSc in pharmacology from the University of London in 1976, an MB BS at St Bartholomew's Hospital in 1979, an MRCS Eng. and LRCP London in 1979, an LMSSA Society of Apothecaries in1979 and a Diploma of Pharmaceutical Medicine from the Royal Colleges of Physicians in 1984. Dr Guy is a member of the editorial board of the Journal of Cannabis Therapeutics.

Scientific Director
Dr Brian Whittle, FRPhS, B Pharm, MSc, PhD

Dr Whittle is a Fellow of The Royal Pharmaceutical Society and of The British Institute of Regulatory Affairs. He is a qualified person under provisions of Directive 75/319/EEC and Directive 81/851/EEC and oversees the scientific development of the programme.

Dr Whittle was co-founder and chief executive of Phytopharm plc from 1990 to 1994 and chief scientific officer from 1994 to 1998. He was previously managing director of Research Consultants (International) Limited, a subsidiary of Ethical Holdings plc, from 1989. He also formed Brian Whittle Associates Limited, a pharmaceutical development consultancy, in 1981. From 1979 to 1981 Dr Whittle was director of regulatory affairs and health registration for Wyeth Europe Limited and from 1969 to 1979 was head of pharmacology at Reckitt and Colman plc. From 1960 to 1969 he was head of the Central Nervous Systems Unit at ICI Pharmaceuticals Limited Prior to that Dr Whittle was a lecturer in Pharmacology at Sunderland University and then a pharmacist at the Royal Marsden Hospital, London.

He was awarded a Bpharm degree from the University of Nottingham in 1954, a PhC Diploma by the Pharmaceutical Society in 9154, an MSc by the University of London in 1957 and a PhD also by the University of London in 1963.

Managing Director
Mr Justin Gover, BSc, MBA

Mr Justin Gover was previously Head of Corporate Affairs at Ethical Holdings plc, the NASDAQ-quoted drug delivery company. In this role, he was responsible for the Company's strategic corporate activities, including mergers and acquisitions, strategic investments, equity financing and investor relations. Transactions included acquisitions and disposals in North and South America, public listings of group companies in London and the US, and strategic investments in Asia. He previously worked as a consultant with BDO Management Consultants in Hong Kong and also in China establishing a pharmaceutical joint venture.

Mr Gover holds an MBA from INSEAD in Fontainebleau, France. He received a BSc (Hons) from Bristol University in 1992.

Finance Director
Mr Jonathan Laughton MA, ACA

Mr Laughton is a member of the Institute of Chartered Accountants in England and Wales and has recently joined GW from the accountancy partnership KPMG.

Mr Laughton holds an MA in Human Sciences from St John's College, Oxford University.

Medical Director
Dr Philip Robson MB, MRCP, FRCPsych
Dr Philip Robson MB, MRCP, FRCPsych Dr Robson joined the company as Medical Director in January, having for the previous ten years been a Consultant Psychiatrist in Oxford and Senior Clinical Lecturer in the Oxford University Department of Psychiatry.

After qualification and some time spent as a hospital doctor in London, Philip worked for eight years within the pharmaceutical industry, initially as a clinical pharmacologist and then as Director of Clinical Research at Wyeth Laboratories. He then left to undergo a training in psychiatry, becoming a full time Clinical Lecturer at Oxford University before being appointed to establish a new Regional Drug Dependency service for Oxfordshire in 1990. He has remained active in research throughout his clinical career and has published more than forty scientific papers and several text-book chapters. His book Forbidden Drugs was first published in 1994 by Oxford University Press, and the second edition appeared in June 1999.

Dr Robson has been interested for many years in the therapeutic potential of cannabis and cannabinoids. In 1996 he was commissioned by the Department of Health to carry out a critical review of the relevant scientific literature, and in 1998 was called on to submit both written and verbal evidence to the House of Lords Science & Technology Committee investigation into cannabis.

In addition to his duties as Medical Director of the company, Dr Robson is also a Senior Research Fellow in the Department of Psychiatry at the University of Oxford.

Director of Research & Development Operations
Mr Colin Stott BSc (Hons)., D.I.S., Dip. Clin. Sci.
Mr Colin Stott BSc (Hons)., D.I.S., Dip. Clin. Sci. Mr. Colin Stott has fourteen years experience in the pharmaceutical industry covering a wide range of new chemical entities, biotechnology products, and plant-based medicines, with 11 years experience of clinical development and project management.

Prior to joining GW Pharmaceuticals, Mr. Stott was Clinical Programme Manager & International Project Leader at Napp Pharmaceuticals Ltd, leading the development of an international joint development programme of a plant-based medicine. Previously to this, Mr. Stott was Clinical Projects Manager at the plant medicines company Phytopharm plc between 1996 and 1999, managing clinical and pre-clinical development programmes. Mr. Stott also has experience gained at Astra Zeneca, Schering-plough, Genzyme and Alpha Therapeutics Ltd (now Grupo Grifols).

Mr. Stott has a background in pharmacology, biochemistry and microbiology and gained a BSc in Medicinal and Pharmaceutical Chemistry and Diploma in Industrial Studies from Loughborough University of Technology in 1988. In 1993, he gained a Distinction in the industry-approved Diploma in Clinical Science at the Welsh School of Pharmacy. He is a member of the Institute of Clinical Research.

Associate Technical Director
Dr Ian Flockhart, PhD BSc Cchem FRSC

Dr Flockhart is a Qualified Person under EU regulations, a Chartered Chemist and a Fellow of The Royal Society of Chemistry. He is also a Member of The Society for Medicines Research, The Analytical Division and Joint Pharmaceutical Analysis Group of The Royal Society of Chemistry and The Controlled Release Society.

Dr Flockhart is Director of Applied Analysis Ltd which performs the chemical analysis and formulation research for GW Pharmaceuticals Ltd. He has been providing pharmaceutical consultancy services since 1984. Between 1978 and 1984 he was Manage of Analytical Services, Reckitt & Colman's Pharmaceutical Division, and Metabolic Studies.

Dr Flockhart is the author of some 35 papers and articles in the fields of biochemical pharmacology, drug metabolism, biopharmaceutics and radiobiology. He has filed as co-inventor on three patent applications for transdermal and transmucosal delivery systems with further patent filings under preparation in th drug delivery system area.

From 1971 to 1978 Dr Flockhart was the Cancer Research Campaign Research Fellow / Lecturer at the Royal Post Graduate Medical Scholl, Hammersmith Hospital, London and at Gray Lab., Mount Vernon Hospital. Between 1970 to 1971 he held a Post Doctoral Fellowship at the University of California, Berkeley. Dr Flockhart received a PhD In Biochemistry from St Mary's Hospital Medical School, University of London in 1970 and holds a BSc (Honours) in Chemistry from Leicester University.

Medical Director (North America)
Dr David Hadorn, MD

Dr Hadorn has worked as a policy analyst and researcher for the British Columbia Ministry of Health, the BC Office of Health Technology Assessment, the US Agency for Health Care Policy and Research, the New Zealand Ministry of Health and the NZ Health Funding Authority. Dr Hadorn recently served as an advisor to the California Attorney General's Task Force on Medical Marijuana and is a member of the editorial board of the Journal of Cannabis Therapeutics.

Dr Hadorn is research director for the Western Canada Waiting List Project, a federally funded project developing clinical criteria for use in the management of waiting lists. Until 1998 he was director of the New Zealand Drug Policy Forum Trust, an independent group of physicians and other professionals who advised government on illicit drug policies.

Dr Hadorn received his MD from the University of California in 1976 and practiced in hospital and A&E departments for 12 years. In 1988 he received a Master's degree in philosophy from the University of Colorado, focussing on health care resource allocation and measurement of quality of life.

Special Counsel, Medical Affairs (North America)
Ms Alice Mead, JD, LL.M
Ms Mead is an attorney specialising in health care law. For the past eleven years, she has served as Legal Counsel to the California Medical Association, the largest state medical association in the United States. During that time, she has developed special expertise in the legal and regulatory issues surrounding the production of medicinal cannabis. Most recently on behalf of the California Attorney General's Task Force on Medical Marijuana, Ms Mead drafted extensive legislation that has gained the support of a broad range of both governmental and private interest groups across California. She has also prepared detailed guidelines on the subject for the medical profession which have been widely adopted throughout the State and nation.

Prior to joining the California Medical Association, Ms Mead served as a litigator for Morrison & Foerster, a large law firm. Ms Mead began her legal career as a law professor at Arizona State University College of Law, where she taught courses in various aspects of federal Constitutional Law.

Ms Mead received her JD degree in 1980 from the University of Santa Clara in California and in 1982 obtained an advanced law degree (LIM) specialising in constitutional theory from the Yale Law School.

Head Of Research Resources
Ms Kim Strong, MA, MSI Dip
Ms Strong previously worked in the private equity and venture capital department of Guernsey International Fund Managers, a subsidiary of Barings, and prior to this was with Rothschilds, first in treasury for NM Rothschild & Sons Ltd. and then in client liaison for Rothschild Asset Management.

Ms Strong is also Executive Director of The Medicinal Cannabis Research Foundation, reporting directly to the Trustees, Lord Butterworth, Lord Kirkwood, Lord Nathan and Lord Rea.

Ms Strong is a Member of the Securities Institute and has an MA in Human Sciences from Oxford University.

Clinical Research Manager
Ms Margaret Flint, RGN

From 1991 to 1999 Ms Flint worked as Clinical Research Associate and then as Senior Clinical Research Associate for Ethical Pharmaceuticals (UK) Ltd.
Previously Ms Flint was the principal research nurse in a contract phase one unit, Clinical Research International, Huntingdon and was also Matron of Brooke House Nursing Home, Norfolk. Ms Flint specialised in neurosurgical nursing at Addenbrooke's Hospital, Cambridge, following completion of RGN training there in 1977.

Formulation Manager
Dr Christina Woollard Ph.D., B.Pharm., M.R.Pharm.S.

Dr Woollard was a Senior Development Scientist at Whitehall International prior to taking the position at GW Pharmaceuticals. In this role, she was responsible for managing formulation development activities of a broad range of dosage forms for International markets, and participated in global project management teams.

Dr Woollard carried out her PhD research at Cardiff University, in the field of pulmonary delivery of liposomes, which included work on gene therapy for cystic fibrosis. Dr Woollard qualified with a first class honours Pharmacy degree from Cardiff University, and completed her pre-registration training at Parke-Davies/Warner Lambert and Royal Gwent Hospital.

Regulatory Affairs Manager
Mrs Alison Thompson BSc Hons.
Prior to joining GW, Mrs Thompson worked in Switzerland and the UK for Novartis on world-wide regulatory projects. From 1990 to 1998, Mrs Thompson built the regulatory and quality framework for a growing Finnish company, Finnfeeds International Ltd, specialising in novel feed additives such as microbially- and plant-derived enzymes. The regulatory work encompassed negotiations with world-wide regulatory authorities including the FDA and USDA in the United States and with the European Commission. Chairmanship of Brussels and UK committees and working closely with the UK and European authorities contributed to ensuring that legislation being introduced for this new area of additives was practical. From 1977-1983, she was an agronomist with Cyanamid of Great Britain. During her university years (Agricultural Botany at Reading University, UK), she worked on plant breeding projects in Canada and Denmark. Mrs Thompson is a member of the British Institute of Regulatory Affairs.